薛俊丽 副主任医师，副教授
硕士招生类型：学术型；专业型
硕士招生专业：肿瘤学；全科医学
博士招生类型：学术型；专业型
博士招生专业：肿瘤学
所在院系：附属东方医院
联系方式：**xuejunli@tongji.edu.cn
课题组链接：
研究方向
主要任职
科研业绩

1. 胃肠道肿瘤神经侵袭及机制( role of Perineural Invasion in GI cancer and possible mechanism)；
2. 外泌体在消化道肿瘤治疗中的作用( role of exosome in GI cancer)；
3. 新药I期临床研究( anti-cancer new drug phase I clinical trial)
国家卫健委能力建设和继续教育肿瘤专家委员会 委员兼秘书Secretary of National Health Commission Oncology Continuing Education Committee
中国医药创新促会抗肿瘤药物临床研究专业委员会副秘书长Vice Secretary of China Pharmaceutical Innovation and Research Development Association (PhIRDA) anti-tumor drug clinical research Committee
中国临床肿瘤学会（CSCO）药物安全管理专家委员会 常委兼秘书Secretary and standing committee member of Anti-cancer drug Safety Management Committee (ASMC), CSCO
中国临床肿瘤学会（CSCO）青年委员会 常委Standing committee member of CSCO YOUNG
中国临床肿瘤学会（CSCO）免疫治疗专家委员会 常委Standing committee member of Immuno-Oncology Committee
中国临床肿瘤学会（CSCO）患者教育委员会 常委Standing committee member of CSCO patients education committee
《肿瘤学杂志》 青年编委Youth editor of Journal of Chinese Oncology
《肿瘤综合治疗电子杂志》 编委Editor of Journal of Multidisciplinary Cancer Manegement (Electric Version)
承担课题：2019年 上海市2019年度“科技创新行动计划”，项目编号：19DZ**，一类抗癌新药呋喹替尼联合信迪利单抗治疗晚期肝细胞癌患者的Ib/II期临床研究，起止时间：2019.10-2022.09；37.5万，在研，主持
2018年 北京医卫健康公益基金会，安罗替尼在晚期胃癌一线治疗中安全性及有效性观察Ib期临床研究，起止时间：2018.7-2021.06；10万，在研，主持；
2018年 东方医院旭日人才计划，10万元；
2017年 科技部慢性重大疾病防治计划，靶向药物治疗胃癌的早期临床研究及多中心大样本临床研究，起止时间：2017.7-2020.12；77万，在研，课题骨干；
Funding Information Current ：1.2019.10-2022.09 Title: Phase I/II clinical trial of Fruquitinib and Sintilimab combination strategy in advanced hepatocellular cell carcinoma.
Grant NO.: 19DZ**, PI (￥375,000)
Major goal: to investigate the safety and effecacy of Fruquitinib and Sintilimab combination strategy in advanced HCC.
2.2018.07-2021.06 Title: phase I clinical trial of Anlotinib in advanced grastric cancer first line treatment
Grant NO.: PI (￥100,000)
Major goal: to investigate the safety and effecacy of Anlotinib in advanced gastric cancer treatment.
3.2018.01-2020.12 Title: Sunrise plan of East Hospital, (￥100,000)
4.2017.07-2020.12 Title: targeted treatment for gastric cancer: early clinical trial and multi-center clinical trial
Grant NO.: 2017YFC** (￥770,000)
Major goal: to find new effective target for gastric cancer treament and investigate new drug for gastric cancer.
Past ：1.2017.07-2020.06 Title: bioequivalence research of Methotrexate in clinical use
Grant NO.: PI ** (￥200,000)
Major goal: to investigate the bioequivalence of Chinese methotrexate and to promote Chinese drug come into market.
2.2016.01-2018.12Title: Role of PIPKIγ intervention in breast cancer CTC Cluster formation via regulating γ-catenin and its possible mechanism
Grant NO.: ** ((￥198,000)
Major goal: to demonstrate the possible prognostic and therapeutic role of PIPKIγ in breast cancer, providing novel way for breast cancer early diagnosis and therapy.
3.2015.01-2017.12Title: the role of CSC in breast cancer metastasis and prognosis, possible mechanism
Grant NO.: PI (￥30,000)
Major goal: to reveal the role of CSC phenotype CTCs during the breast cancer metastasis, and take effective measure to prevent the metastasis and improve patients prognosis
4.2014.07-2017.07Title: Shanghai Outstanding Youth Doctor program ，PI (￥100,000)
5.2013.11-2016.10Title: The Relationship of CTC and Coagulation Situation in Gastric Cancer Patients
Grant NO.: DFZY-12 PI (￥30,000)
Major goal: We will find the relationship between CTC and coagulation situation and thrombosis in Gastric cancer patients, and whether anticoagulation may treatment could control or prevent cancer metastasis
发表论文：1.Wei Peng, Wei Huang, Liqiong Xue, Xiaoxiao Ge, Wei Zhao, Junli Xue#. Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. EBioMedicine, 2019, 44: 375-386.
2.Junli Xue, Xuetao Yu?, ?Liqiong Xue, Xiaoxiao Ge, Wei Zhao, Wei Peng. Intrinsic β-catenin signaling suppresses CD8?+ T-cell infiltration in colorectal cancer. Biomedicine & Pharmacotherapy. 2019, 115: 108921.
3.Junli Xue, Chunhua Chen, Manlong Qi, Kun Ling. Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB., Oncotarget, 2017.6.27, 8(26): 42414~42427.
4.Xing Jiang, Yong Zhou, Ai-Jun Sun, Jun-Li Xue# NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1, J Cell Physiol, 2018, 233(11):8558-8566.
5.Junli Xue, Victoria K. Xie, Peipei Wang, Jiujie Cui, Yong Gao, and Zhimin Lu. Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs. Curr Pharm Des. 2014; 20(33): 5298–5308.